SCHEMBL5648185

SCHEMBL5648185

CS(=O)(=O)Nc1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.38
ALDH1A1 P00352 4/20 0.35
GAA P10253 4/20 0.35
HSD17B10 Q99714 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
BRD4 O60885 3/20 0.33
KMT2A Q03164 2/20 0.33
KEAP1 Q14145 1/20 0.33
PTGS2 P35354 2/20 0.33
ALOX5 P09917 1/20 0.33
ALOX15 P16050 1/20 0.33
NR3C1 P04150 2/20 0.32
PGR P06401 1/20 0.32
NR3C2 P08235 1/20 0.32
AR P10275 1/20 0.32
LMNA P02545 2/20 0.32
PI4KA P42356 1/20 0.32
PIK3CG P48736 1/20 0.32
MAPK8 P45983 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652117 0.81 CYP1A2 (0.41) MAT2AALDH1A1GAAKDM4EKMT2A
SCHEMBL5648821 0.80 LMNA (0.43) ALDH1A1GAAKDM4EKMT2ALMNA
SCHEMBL2784878 0.80 KMT2A (0.40) MAT2AALDH1A1GAAHPGDKMT2A
SCHEMBL5650652 0.80 ADORA3 (0.38) ALDH1A1GAAKDM4EHPGDKMT2A
SCHEMBL5648743 0.78 IKBKB (0.40) ALDH1A1KDM4EKMT2ALMNAMAPT
SCHEMBL5648087 0.78 KMT2A (0.33) MAT2AALDH1A1GAAKDM4EKMT2A
SCHEMBL5651010 0.76 KMT2A (0.35) ALDH1A1GAAKMT2ALMNA
SCHEMBL5653932 0.76 ABL1 (0.38) ALDH1A1GAAKDM4ELMNAMAPT
SCHEMBL5652751 0.75 LMNA (0.34) ALDH1A1GAAKDM4EKMT2AALOX15
SCHEMBL5654089 0.75 KMT2A (0.38) ALDH1A1GAAHSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAT2A 3154/4885ALDH1A1 1498/4885GAA 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.